News | May 14, 2025
Sai Life Sciences FY25 PAT higher by 105% to Rs. 170 Cr
PAT stood at Rs. 88 crore for Q4 FY25 as compared to Rs. 56 crore in Q4FY24, an increase of 57%
PAT stood at Rs. 88 crore for Q4 FY25 as compared to Rs. 56 crore in Q4FY24, an increase of 57%
The change of name has been carried on pursuant to the Scheme of Amalgamation
This outcome reflects Innoxel Lifesciences' ongoing commitment to maintaining the highest standards of quality, compliance, and regulatory excellence
RPG Life Sciences has reported total income of Rs. 148.15 crores during the period ended March 31, 2025
Over the last 24 years, the company's sales has grown from Rs. 478 crores to Rs. 19,022 crores
This recertification of Company's OECD GLP is testimony to company's unwavering commitment to maintain international quality standards at the facility
The closing of the Block Acquisition is now expected to be completed by Q3 2025
The company has received final approval from the Department of Pharmaceuticals, Government of India, for foreign investment under applicable regulations
The partnership provides Sai Life Sciences with a greenhouse gas emissions reduction of up to 90% for its international logistics needs by using SAF
Deflazacort is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older
Subscribe To Our Newsletter & Stay Updated
